DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
24,900
-400 (-1.58%)
Apr 28, 2026, 3:30 PM KST
62.11%
Market Cap 1.14T
Revenue (ttm) 926.88B
Net Income (ttm) 66.02B
Shares Out 45.11M
EPS (ttm) 1,475.00
PE Ratio 17.15
Forward PE 13.43
Dividend 200.00 (0.79%)
Ex-Dividend Date Dec 29, 2025
Volume 338,185
Average Volume 1,066,988
Open 25,300
Previous Close 25,300
Day's Range 24,700 - 25,300
52-Week Range 15,030 - 31,250
Beta 0.09
RSI 51.17
Earnings Date May 15, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,233
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements

News

There is no news available yet.